VisionCare Ophthalmic Technologies, Inc. announced that it has received a Health Canada medical device license to market the implantable miniature telescope in Canada. The telescope implant is an integral component of a new patient care program called CentraSight, which has been developed to improve vision and quality of life in patients with end-stage age-related macular degeneration (AMD). The CentraSight treatment program involves a patient management process and access to reimbursement information for patients and physicians.

Smaller than a pea, the telescope implant uses micro-optical technology to magnify images which would normally be seen in one's straight ahead or central, vision. The images are projected onto the healthy portion of the retina not affected by the disease, making it possible for patients to see or discern the central vision object of interest.